前列腺癌经典内分泌治疗安全共识

2018-04-30 中国医促会泌尿健康促进分会 现代泌尿外科杂志.2018.23(4):248-258.

为了进一步抑制前列腺癌患者机体下丘脑-垂体-睾丸轴以外雄激素的作用,甾体类(雌激素、孕酮等)和非甾体类抗雄药物(比卡鲁胺、氟他胺、尼鲁米特)先后被尝试在前列腺癌内分泌临床治疗中与手术/药物去势联合应用(CAB)。由于非甾体类药物在疗效和安全性方面的明显优势,非甾体类药物已经成为前列腺癌联合内分泌治疗的首选。 尽管由LHRH 激动剂、睾丸去势手术和非甾体类/甾体类抗雄药物单独或联合使用已经成为治疗前

中文标题:

前列腺癌经典内分泌治疗安全共识

发布日期:

2018-04-30

简要介绍:

为了进一步抑制前列腺癌患者机体下丘脑-垂体-睾丸轴以外雄激素的作用,甾体类(雌激素、孕酮等)和非甾体类抗雄药物(比卡鲁胺、氟他胺、尼鲁米特)先后被尝试在前列腺癌内分泌临床治疗中与手术/药物去势联合应用(CAB)。由于非甾体类药物在疗效和安全性方面的明显优势,非甾体类药物已经成为前列腺癌联合内分泌治疗的首选。 尽管由LHRH 激动剂、睾丸去势手术和非甾体类/甾体类抗雄药物单独或联合使用已经成为治疗前列腺癌的经典方案,但如何针对前列腺癌的不同阶段、不同治疗目的、不同病理类(亚)型及不同患者采用安全合理的内分泌治疗方案仍需引起医患双方的高度重视。 本共识将从条件保障、人员培训、内分泌治疗适应证和治疗方案的合理化选择、内分泌治疗并发症防治和患者管理等方面,以安全为主线,多角度推荐前列腺癌患者经典内分泌治疗的原则意见,希望本共识能使经典的前列腺癌内分泌治疗方案在中国前列腺癌患者治疗中得到更加合理、安全的应用,造福患者。

拓展指南:前列腺癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=前列腺癌经典内分泌治疗安全共识)] GetToolGuiderByIdResponse(projectId=1, id=4c8ca1c00159293c, title=前列腺癌经典内分泌治疗安全共识, enTitle=, guiderFrom=现代泌尿外科杂志.2018.23(4):248-258., authorId=null, author=, summary=为了进一步抑制前列腺癌患者机体下丘脑-垂体-睾丸轴以外雄激素的作用,甾体类(雌激素、孕酮等)和非甾体类抗雄药物(比卡鲁胺、氟他胺、尼鲁米特)先后被尝试在前列腺癌内分泌临床治疗中与手术/药物去势联合应用(CAB)。由于非甾体类药物在疗效和安全性方面的明显优势,非甾体类药物已经成为前列腺癌联合内分泌治疗的首选。 尽管由LHRH 激动剂、睾丸去势手术和非甾体类/甾体类抗雄药物单独或联合使用已经成为治疗前, cover=, journalId=null, articlesId=null, associationId=1623, associationName=中国医促会泌尿健康促进分会, associationIntro=, copyright=0, guiderPublishedTime=Mon Apr 30 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>为了进一步抑制前列腺癌患者机体下丘脑-垂体-睾丸轴以外雄激素的作用,甾体类(雌激素、孕酮等)和非甾体类抗雄药物(比卡鲁胺、氟他胺、尼鲁米特)先后被尝试在前列腺癌内分泌临床治疗中与手术/药物去势联合应用(CAB)。由于非甾体类药物在疗效和安全性方面的明显优势,非甾体类药物已经成为前列腺癌联合内分泌治疗的首选。 尽管由LHRH 激动剂、睾丸去势手术和非甾体类/甾体类抗雄药物单独或联合使用已经成为治疗前列腺癌的经典方案,但如何针对前列腺癌的不同阶段、不同治疗目的、不同病理类(亚)型及不同患者采用安全合理的内分泌治疗方案仍需引起医患双方的高度重视。 本共识将从条件保障、人员培训、内分泌治疗适应证和治疗方案的合理化选择、内分泌治疗并发症防治和患者管理等方面,以安全为主线,多角度推荐前列腺癌患者经典内分泌治疗的原则意见,希望本共识能使经典的前列腺癌内分泌治疗方案在中国前列腺癌患者治疗中得到更加合理、安全的应用,造福患者。</div> <div><br> </div>拓展指南:<strong>与<font color=red>前列腺癌</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=324591c0015e95cc" title="2018 GETUG建议:中度前列腺癌大分割放疗的剂量限制" target=_blank>2018 GETUG建议:中度前列腺癌大分割放疗的剂量限制</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9fb421c0015e764f" title="NCCN临床实践指南:前列腺癌早期检测(2018.V2)" target=_blank>NCCN临床实践指南:前列腺癌早期检测(2018.V2)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=0fa341c0015e557a" title="前列腺癌化疗安全共识" target=_blank>前列腺癌化疗安全共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9a1df1c00156801b" title="NCCN临床实践指南:前列腺癌早期检测(2018.V1)" target=_blank>NCCN临床实践指南:前列腺癌早期检测(2018.V1)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=fbadf1c00155a53e" title="前列腺特异性膜抗原靶向分子影像检查在前列腺癌患者中应用的中国专家共识" target=_blank>前列腺特异性膜抗原靶向分子影像检查在前列腺癌患者中应用的中国专家共识</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%89%8D%E5%88%97%E8%85%BA%E7%99%8C" target=_blank>有关前列腺癌更多指南</a></ul>, tagList=[TagDto(tagId=781, tagName=前列腺癌), TagDto(tagId=1511, tagName=内分泌治疗)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6261, appHits=437, showAppHits=6, pcHits=4260, showPcHits=2443, likes=127, shares=11, comments=6, approvalStatus=1, publishedTime=Fri May 18 23:15:52 CST 2018, publishedTimeString=2018-04-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri May 18 23:15:52 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 08:07:37 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=前列腺癌经典内分泌治疗安全共识)])
前列腺癌经典内分泌治疗安全共识
下载请点击:
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=317081, encodeId=110a31e0810f, content=谢谢了.学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Mon May 21 05:54:52 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316596, encodeId=63a53165960f, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat May 19 09:51:50 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316576, encodeId=8e5d3165e690, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sat May 19 09:23:59 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316552, encodeId=a0a63165520a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/30/21f1f0d02514796066d52523c747be51.jpg, createdBy=75a31960463, createdName=zdvfsadb, createdTime=Sat May 19 08:07:40 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316496, encodeId=aa733164963c, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat May 19 06:26:26 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-21 txqjm

    谢谢了.学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=317081, encodeId=110a31e0810f, content=谢谢了.学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Mon May 21 05:54:52 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316596, encodeId=63a53165960f, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat May 19 09:51:50 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316576, encodeId=8e5d3165e690, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sat May 19 09:23:59 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316552, encodeId=a0a63165520a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/30/21f1f0d02514796066d52523c747be51.jpg, createdBy=75a31960463, createdName=zdvfsadb, createdTime=Sat May 19 08:07:40 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316496, encodeId=aa733164963c, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat May 19 06:26:26 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-19 神功盖世

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=317081, encodeId=110a31e0810f, content=谢谢了.学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Mon May 21 05:54:52 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316596, encodeId=63a53165960f, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat May 19 09:51:50 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316576, encodeId=8e5d3165e690, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sat May 19 09:23:59 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316552, encodeId=a0a63165520a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/30/21f1f0d02514796066d52523c747be51.jpg, createdBy=75a31960463, createdName=zdvfsadb, createdTime=Sat May 19 08:07:40 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316496, encodeId=aa733164963c, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat May 19 06:26:26 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-19 龙胆草

    学习谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=317081, encodeId=110a31e0810f, content=谢谢了.学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Mon May 21 05:54:52 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316596, encodeId=63a53165960f, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat May 19 09:51:50 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316576, encodeId=8e5d3165e690, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sat May 19 09:23:59 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316552, encodeId=a0a63165520a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/30/21f1f0d02514796066d52523c747be51.jpg, createdBy=75a31960463, createdName=zdvfsadb, createdTime=Sat May 19 08:07:40 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316496, encodeId=aa733164963c, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat May 19 06:26:26 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-19 zdvfsadb

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=317081, encodeId=110a31e0810f, content=谢谢了.学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Mon May 21 05:54:52 CST 2018, time=2018-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316596, encodeId=63a53165960f, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat May 19 09:51:50 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316576, encodeId=8e5d3165e690, content=学习谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Sat May 19 09:23:59 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316552, encodeId=a0a63165520a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/30/21f1f0d02514796066d52523c747be51.jpg, createdBy=75a31960463, createdName=zdvfsadb, createdTime=Sat May 19 08:07:40 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316496, encodeId=aa733164963c, content=了解了解.学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sat May 19 06:26:26 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-19 1dd8c52fm63(暂无匿称)

    了解了解.学习学习

    0